#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3168	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2499	375.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1625	1625	C	449	C	368	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4828	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3825	376.7	0	.	n	.	0	T695C	SNP	695	695	T	1114	1114	C	393	C,A,G	312,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4828	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3825	376.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1756	1756	A	394	A	320	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4828	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3825	376.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2390	2390	C	482	C	388	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4828	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3825	376.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3016	3016	T	392	T,C,G,A	238,79,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4828	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3825	376.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2464	2464	A	469	A	365	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	478	folP	852	852	100.0	folP.l15.c4.ctg.1	2076	68.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1278	1280	AGC	107;110;111	A;G;C	82;89;84	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	962	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3754	76.6	1	SNP	p	S91F	0	.	.	271	273	TCC	752	754	TCC	92;91;92	T;C;C	71;72;74	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	962	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3754	76.6	1	SNP	p	D95N	0	.	.	283	285	GAC	764	766	GAC	90;91;91	G;A;C,G	71;73;70,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	962	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3754	76.6	1	SNP	p	D95G	0	.	.	283	285	GAC	764	766	GAC	90;91;91	G;A;C,G	71;73;70,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	472	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1843	76.4	1	SNP	p	G45D	1	.	.	133	135	GAC	734	736	GAC	136;136;137	G;A,G;C	106;101,1;108	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	248	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1293	57.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1160	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3236	106.9	1	SNP	p	D86N	0	.	.	256	258	GAC	718	720	GAC	138;137;138	G;A;C	108;101;107	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1160	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3236	106.9	1	SNP	p	S87W	0	.	.	259	261	AGT	721	723	AGT	137;137;137	A,G,C;G;T,C	104,1,1;105;102,2	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1160	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3236	106.9	1	SNP	p	S87R	0	.	.	259	261	AGT	721	723	AGT	137;137;137	A,G,C;G;T,C	104,1,1;105;102,2	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1160	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3236	106.9	1	SNP	p	S87I	0	.	.	259	261	AGT	721	723	AGT	137;137;137	A,G,C;G;T,C	104,1,1;105;102,2	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1160	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3236	106.9	1	SNP	p	S88P	0	.	.	262	264	TCC	724	726	TCC	137;137;137	T;C;C,T	102;110;110,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	872	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3056	85.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1822	1824	GGC	123;122;122	G;G;C	98;101;97	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1435	1437	GCA	116;116;117	G,A;C;A	89,1;90;94	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1438	1440	ATC	117;117;116	A,C;T;C	89,1;88;92	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1450	1452	GTG	113;113;114	G;T,G;G,A	97;92,1;95,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1450	1452	GTG	113;113;114	G;T,G;G,A	97;92,1;95,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1954	1956	ACC	97;97;98	A;C;C	78;80;82	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2008	2010	GCG	93;91;93	G,C;C,G;G	73,1;70,1;74	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2008	2010	GCG	93;91;93	G,C;C,G;G	73,1;70,1;74	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2131	2133	GGC	80;80;80	G;G;C	61;65;64	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2140	2142	GGC	83;84;84	G;G;C	64;65;66	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	778	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2739	84.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2158	2160	CCG	84;86;86	C;C;G	63;66;64	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1086	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3342	97.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	554	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2145	77.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	688	688	C	91	C	74	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	G38E	NONSYN	112	114	GGA	546	548	GAA	90;92;92	G;A;A	78;79;78	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	576	578	GGA	95;94;94	G;G;A	84;80;83	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	T87A	NONSYN	259	261	ACT	693	695	GCT	100;100;99	G;C;T	85;85;84	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	699	701	AGC	102;102;102	A;G;C	87;86;87	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	791	792	CG	99;99	C;G	85;83	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	794	796	CAG	99;99;99	C,A;A;G,A	81,1;83;84,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	798	800	AAA	99;100;101	A;A;A	85;87;84	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	861	863	GAA	109;111;113	G;A;A	89;92;91	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	885	887	GCA	110;110;110	G;C;A	86;86;86	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1068	1070	GAT	111;112;112	G;A;T	96;93;95	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1071	1073	GGT	112;111;111	G;G;T	97;96;95	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1086	1088	ATG	112;113;114	A;T;G	94;95;96	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1200	1202	GCA	108;108;108	G;C;A	93;92;95	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1203	1205	ACG	107;107;107	A;C;G	91;92;92	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1206	1208	GGG	107;107;106	G;G,T;G,T	91;89,1;89,2	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1209	1211	GTT	105;104;103	G;T;T	93;90;89	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1269	1271	GTA	121;121;122	G;T;A,G	96;96;93,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1308	1310	ACT	127;127;127	A;C;T,G	103;103;104,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1314	1316	GAT	127;125;125	G;A;T	100;98;98	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1326	1328	CAC	125;124;123	C;A;C	99;100;103	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	1	SNP	p	G120K	1	.	.	358	360	AAG	791	793	CGG	99;99;99	C;G;G	85;83;85	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	1	SNP	p	D121N	0	.	.	361	363	GAC	794	797	CGC	99;99;99	C,A;G,A;C	81,1;84,1;87	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	550	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1707	91.8	1	SNP	p	A121D	1	.	.	361	363	GAC	794	797	CGC	99;99;99	C,A;G,A;C	81,1;84,1;87	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2118	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5165	122.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2162	2164	AAT	109;109;109	A;A,C;T	88;88,1;87	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	358	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1370	78.0	1	SNP	p	V57M	1	.	.	169	171	ATG	752	754	ATG	138;138;137	A;T;G,A	114;114;112,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
